Monopar Therapeutics Files 8-K
Ticker: MNPR · Form: 8-K · Filed: Apr 10, 2024 · CIK: 1645469
| Field | Detail |
|---|---|
| Company | Monopar Therapeutics (MNPR) |
| Form Type | 8-K |
| Filed Date | Apr 10, 2024 |
| Risk Level | low |
| Pages | 1 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 8-K, disclosure, financials
TL;DR
Monopar filed a routine 8-K, no major news.
AI Summary
Monopar Therapeutics Inc. filed an 8-K on April 10, 2024, to report a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific details on financial performance or material events beyond the standard reporting requirements.
Why It Matters
This 8-K filing serves as a routine disclosure for Monopar Therapeutics, indicating the submission of required financial statements and exhibits to the SEC.
Risk Assessment
Risk Level: low — The filing is a standard 8-K for financial statements and exhibits, not indicating any new material events or risks.
Key Players & Entities
- Monopar Therapeutics Inc. (company) — Registrant
- April 10, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 1000 Skokie Blvd. , Suite 350 , Wilmette , IL 60091 (address) — Principal executive offices
- 847-388-0349 (phone_number) — Registrant's telephone number
FAQ
What is the primary purpose of this 8-K filing by Monopar Therapeutics?
The primary purpose of this 8-K filing is to report a Regulation FD Disclosure and to provide Financial Statements and Exhibits as required by the SEC.
On what date was the earliest event reported in this filing?
The earliest event reported in this filing was on April 10, 2024.
In which state is Monopar Therapeutics Inc. incorporated?
Monopar Therapeutics Inc. is incorporated in Delaware.
What is the address of Monopar Therapeutics' principal executive offices?
The address of Monopar Therapeutics' principal executive offices is 1000 Skokie Blvd., Suite 350, Wilmette, IL 60091.
Does this filing announce any specific new business developments or financial results?
This filing does not explicitly announce specific new business developments or detailed financial results; it primarily serves as a notification of required disclosures and exhibits.
Filing Stats: 448 words · 2 min read · ~1 pages · Grade level 10.4 · Accepted 2024-04-10 08:00:39
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value MNPR The Nasdaq Stock Mar
Filing Documents
- mnpr20240402_8k.htm (8-K) — 25KB
- ex_649393.htm (EX-99.1) — 11KB
- monologo.jpg (GRAPHIC) — 4KB
- 0001437749-24-011573.txt ( ) — 181KB
- mnpr-20240410.xsd (EX-101.SCH) — 3KB
- mnpr-20240410_def.xml (EX-101.DEF) — 12KB
- mnpr-20240410_lab.xml (EX-101.LAB) — 16KB
- mnpr-20240410_pre.xml (EX-101.PRE) — 12KB
- mnpr20240402_8k_htm.xml (XML) — 3KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On April 10, 2024, Monopar Therapeutics Inc. (Monopar) issued a press release announcing that its Phase 1 dosimetry clinical trial for its novel radiopharmaceutical imaging agent MNPR-101-Zr (MNPR-101 conjugated to zirconium-89) is now active and recruiting patients with advanced cancers. The press release is furnished as Exhibit 99.1 to this report and incorporated herein by reference.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits Exhibit No. Description 99.1 Press Release Dated April 10, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Monopar Therapeutics Inc. Date: April 10, 2024 By: /s/ Kim R. Tsuchimoto Name: Kim R. Tsuchimoto Title: Chief Financial Officer and Director